Top

Press Release

XtalPi integrates quantum physics and AI to create computational drug discovery and development applications that accurately predict important drug properties of small molecules, helping researchers accelerate and de-risk pharmaceutical innovations.

XtalPi announces the closing of $46 million Series B-1 extension to drive growth and accelerate platform development

CAMBRIDGE, Mass., Oct 24, 2018 – XtalPi Inc, a computation-driven biotech startup integrating quantum physics, artificial intelligence (AI), and cloud computing to empower pharmaceutical research, today announced a Series B-1 extension financing of $46 million to support XtalPi’s continuous market growth and expand the application...

Read More

XtalPi Inc. Announces Strategic Research Collaboration with Pfizer Inc. to Develop Artificial Intelligence-Powered Molecular Modeling Technology for Drug Discovery

CAMBRIDGE, Mass., May 8, 2018 –XtalPi Inc. (“XtalPi”), a computation-driven pharmaceutical technology company, announced today a strategic research collaboration with Pfizer Inc. (NYSE:PFE) (“Pfizer”) to develop a hybrid physics- and artificial intelligence (AI)-powered software platform for accurate molecular modeling of drug-like small molecules.   This state-of-the-art platform...

Read More

XtalPi and AMRI’s SSCI Enter into Joint Research Agreement to Apply Computational Technologies to Solid-Form Pharmaceutical Research Challenges

  Boston, Mass., (July 21, 2017) –XtalPi Inc., a pharmaceutical technology company offering intelligent digital drug development solutions to empower more efficient pharmaceutical research, is joining forces with AMRI SSCI, LLC (SSCI), a division of Albany Molecular Research, Inc. (AMRI), to identify solid forms of small...

Read More